|
gptkbp:instanceOf
|
gptkb:drug
iron preparation
|
|
gptkbp:administeredBy
|
solution for injection
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2007 (Europe)
2013 (USA)
|
|
gptkbp:ATCCode
|
B03AC06
|
|
gptkbp:brand
|
gptkb:Ferinject
Injectafer
|
|
gptkbp:CASNumber
|
9007-72-1
|
|
gptkbp:chemicalFormula
|
C18H34FeO16
|
|
gptkbp:containsElement
|
iron(III)
|
|
gptkbp:contraindication
|
iron overload
anemia not caused by iron deficiency
hypersensitivity to ferric carboxymaltose
|
|
gptkbp:discoveredBy
|
gptkb:Vifor_Pharma
|
|
gptkbp:eliminationHalfLife
|
7-12 hours
|
|
gptkbp:form
|
solvent
|
|
gptkbp:hasComponent
|
carboxymaltose
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ferric carboxymaltose
|
|
gptkbp:indication
|
iron deficiency in adults
iron deficiency in children
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:maximumDose
|
1000 mg per week
|
|
gptkbp:mechanismOfAction
|
provides bioavailable iron for erythropoiesis
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
B3 (Australia)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
dizziness
hypertension
flushing
hypophosphatemia
|
|
gptkbp:storage
|
store below 30°C
|
|
gptkbp:UNII
|
7VQ8PS73EZ
|
|
gptkbp:usedFor
|
treatment of iron deficiency anemia
|
|
gptkbp:bfsParent
|
gptkb:Ferinject
|
|
gptkbp:bfsLayer
|
8
|